Contact:  Ilana Nikravesh
               Mount Sinai Press Office
               [email protected]

Mount Sinai Researchers Discover New Technique to Treat Osteochondral Ankle Lesions
Minimally invasive approach may lead to quicker recovery

Newswise — (New York, NY – September 24, 2018) – Mount Sinai researchers have discovered a new, minimally invasive strategy for treating osteochondral defects of the ankle bone, common injuries that are typically caused by ankle sprains. The strategy involves injecting bone substitute material into the injury, which they showed could cut recovery time in half compared to the standard surgical treatment, in a study published in the September/October issue of Orthopedics.

“This technique is a completely new way of looking at a common orthopedic condition which is typically seen in younger patients and athletes, and this minimally invasive approach could make recovery much easier,” said lead investigator Ettore Vulcano, MD, Assistant Professor of Orthopedics at the Icahn School of Medicine at Mount Sinai.

“This is the first published study looking at the use of injectable bone substitute to treat the pain instead of cartilage grafts, and if results continue to be positive this technique can substantially change the way surgeons treat this debilitating condition.”

Osteochondral lesions of the ankle bone happen when there’s a tear or fracture in the cartilage covering the bone.  These commonly affect active younger people, including athletes.  Traumatic injuries including ankle sprains often cause them, leading to significant pain when weight is put on the injury. The standard treatment typically consists of surgical procedures to stimulate cartilage growth, including grafts or scraping, which require six to eight weeks of no walking, plus another six weeks in a surgical boot. Even with this treatment, the recurrence rate remains high.

Dr. Vulcano and a team of researchers looked at whether the subchondroplasty procedure (SCP), a less invasive treatment, would be more effective.  SCP entails making micro-incisions to inject calcium phosphate bone substitute into the bone.  During the healing process, real bone replaces the hard-setting bone substitute material.    

“I do not believe the actual cartilage lesion is the source of pain. Therefore, my hypothesis was that if I address the bone bruising with bone substitute without even touching the cartilage or trying to regenerate cartilage, the patient will get pain relief,” added Dr. Vulcano.

Researchers studied 11 patients with osteochondral defects who underwent SCP (4 male and 7 female, mean age 34 years). They analyzed their recovery over the course of nine months.  Dr. Vulcano and the team found that 90 percent of the patients could bear weight on their ankle immediately after the procedure and had excellent pain relief.  One patient could run without pain only three weeks following treatment.  With traditional surgery, there’s also a 90 percent success rate, but patients are not allowed to bear weight on the surgical foot for up to two months.

“Further studies are needed to assess the long-term effectiveness of this procedure, but this may represent an additional method to treat a difficult condition with a quick recovery,” Dr. Vulcano explained.

About Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest integrated delivery system encompassing seven hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai’s vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The System includes approximately 6,600 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools”, aligned with a U.S. News & World Report’s “Honor Roll” Hospital, it is ranked as a leading medical school for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report’s “Honor Roll” of top U.S. hospitals; it is one of the nation’s top 20 hospitals in Cardiology/Heart Surgery, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in six other specialties in the 2018-2019 “Best Hospitals” issue. Mount Sinai’s Kravis Children’s Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology and 44th for Ear, Nose, and Throat, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s and Mount Sinai West are ranked regionally. For more information, visit, or find Mount Sinai on Facebook, Twitter and YouTube.